<DOC>
	<DOCNO>NCT00875745</DOCNO>
	<brief_summary>The purpose study test safety sorafenib vorinostat give together see effect ( good bad ) patient acute myeloid leukemia ( AML ) myelodysplastic syndrome ( MDS ) . This study also do find high dose sorafenib vorinostat give together without cause severe side effect .</brief_summary>
	<brief_title>Combination Sorafenib Vorinostat Poor-risk Acute Myelogenous Leukemia ( AML ) High Risk Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients must diagnosis AML ( &gt; 20 % myeloid blast peripheral blood bone marrow ) MDS &gt; 10 % myeloid blast bone marrow . Patients Acute Promyelocytic Leukemia ( APL ) must refractory alltrans retinoic acid ( ATRA ) arsenic trioxide . The patient must one follow criterion : Age 18 69 year ; relapse refractory disease follow least one prior therapeutic regimen ; candidate cytotoxic conventional therapy due disease refractoriness , poor performance status , comorbidities Age 70 year old ; receive previous therapy ( hematopoietic growth factor hydroxyurea ) ; candidate cytotoxic conventional therapy due poor performance status , comorbidities , personal preference Age 70 year old relapse refractory disease The patient must discontinue previous therapy acute leukemia least 14 day recover acute effect therapy . Patients must ECOG ( Zubrod ) performance status 02 Patients must able take tolerate oral medication Patients must adequate organ function specify protocol . Patients anticoagulation must INR &lt; 1.5 PTT within normal limit . Pregnant woman nurse mother eligible trial . Patients may receive concurrent biologic therapy , cytotoxic chemotherapy radiation therapy trial . Patients one serious preexist medical condition , opinion investigator , would preclude participation study . See protocol listing . Patients known central nervous system ( CNS ) leukemia spinal fluid cytology , flow cytometry image Patients previous autologous allogeneic stem cell transplantation current side effect and/or complication opinion investigator interfere interpretation toxicity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>